BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
- Conditions
- Kidney Failure, ChronicHealthy VolunteersRenal Impairment
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06723535
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT06715683
- Locations
- 🇺🇸
Anaheim Clinical Trials (ACT), Anaheim, California, United States
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 833
- Registration Number
- NCT06710470
- Locations
- 🇺🇸
Bristol-Meyers Squibb, Lawrenceville, New Jersey, United States
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT06701513
- Locations
- 🇫🇷
Local Institution - 060, Amiens cedex 1, France
🇫🇷Cabinet Médical Elisabeth Lion, Angers, France
🇫🇷Local Institution - 045, Argenteuil, France
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT06698887
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 413
- Registration Number
- NCT06697197
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Local Institution - 0005, Irvine, California, United States
🇺🇸Local Institution - 0030, Los Angeles, California, United States
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
- Conditions
- Advanced Solid Tumors With Homozygous MTAP Deletion
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT06672523
- Locations
- 🇭🇺
ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- Biological: BMS-986489 (BMS-986012+Nivolumab)
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 530
- Registration Number
- NCT06646276
- Locations
- 🇺🇸
Local Institution - 0337, Daphne, Alabama, United States
🇺🇸Local Institution - 0283, Hot Springs, Arkansas, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT06618287
- Locations
- 🇺🇸
Local Institution - 0066, Birmingham, Alabama, United States
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇨🇦The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
A Real-World Study of Β-Thalassemia Major Treatment with Luspatercept in Taiwan
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 90
- Registration Number
- NCT06596642
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳MacKay Memorial Hospital, Taipei, Taiwan